Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Mar 30;122(7):911-912.
doi: 10.1161/CIRCRESAHA.118.312860.

Complementing T Regulatory Cells to Combat Hypertension

Keisa W Mathis  1
Affiliations
Editorial

Complementing T Regulatory Cells to Combat Hypertension

Keisa W Mathis. Circ Res. .
No abstract available

Keywords: Editorials; blood pressure; complement activation; forkhead transcription factors; hypertension; inflammation.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Therapeutic applicability of enhancing T regulatory cells
There is strong evidence that blockade of complement activation product signaling through the C3a receptor (C3aR) and C5aR enhances the anti-inflammatory function of T regulatory cells (Tregs). Other mechanisms have also been effective in augmenting Tregs. For example, activation of a particular neuroimmune axis (termed the cholinergic anti-inflammatory pathway) via vagus nerve stimulation increases Tregs. In addition, in vivo stimulation of Tregs using an anti-CD28 superagonistic monoclonal antibody, and ex vivo/in vitro stimulation via anti-CD28/CD3 monoclonal antibody-coated beads both are known to modulate Tregs. Because the reduction of Tregs is usually pathogenic and because adoptive transfer of Tregs has been shown to be therapeutic, it is important to effectively optimize methods to enhance Tregs to potentially combat chronic inflammatory disorders with oxidative stress including renal diseases, vascular diseases, and importantly, hypertension.
See this image and copyright information in PMC

Comment on

References

    1. Whelton P, Carey R, Aronow W, Casey D, Collins K, Himmelfarb C, DePalma S, Gidding S, Jamerson K, Jones D, MacLaughlin E, Muntner P, Ovbiagele B, Smith S, Spencer C, Stafford R, Taleer S, Thomas R, Williams K, Williamson J, Wright J. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Journal of the American College of Cardiology. 2017 (In press) - PubMed
    1. Rodriguez-Iturbe B, Pons H, Johnson R. Role of the immune system in hypertension. Physiological Reviews. 2017;97:1127–1164. - PMC - PubMed
    1. Harrison D, Guzik T, Lob H, Madhur M, Marvar P, Thabet S, Vinh A, Weyand C. Inflammation, Immunity and Hypertension. Hypertension. 2011;57:132–140. - PMC - PubMed
    1. Chen X, Ruan C, Ge Q, Ma Y, Xu J, Zhang Z, Lin J, Chen D, Zhu D, Gao P. Deficiency of complement C3a and C5a receptors prevent angiotensin II-induced hypertension via regulatory T cells. Circulation Research. 2018 In press. - PubMed
    1. Ricklin D, Reis E, Lambris J. Complement in disease: a defence system turning offensive. Nature Reviews: Nephrology. 2016;12:383–401. - PMC - PubMed